Immutep Limited

12/10/2025

Immutep Limited is pleased to complete another productive meeting with the FDA regarding the eftilagimod alfa (efti) program. We welcome the positive feedback and the agreement on efti's optimal biological dose is another important building block for future potential BLA filings.

Announcement here: http://bit.ly/4ogdyWA

09/10/2025

Immutep Limited announces update for pivotal TACTI-004 Phase III in 1L NSCLC.

Immutep has now enrolled & randomised over 170 patients, an important milestone as this is above the # required to conduct the futility analysis, which remains on track for Q1 2026.

Additionally, the # of activated clinical sites continues to expand at a strong pace, now exceeding 100 across 24 countries.

Read more here: http://bit.ly/42wziFq

22/09/2025

We’re pleased to share that George Washington University Cancer Center, will launch an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patients. The trial is led by Dr. Pavani Chalasani, MD, MPH, Division Director of Hematology and Medical Oncology and aims to assess pathological complete response (pCR) following neoadjuvant efti and chemotherapy treatment.

Read more here http://bit.ly/3W6wBqd

16/09/2025

Immutep Limited CEO Marc Voigt recently joined ShareCafe’s Lauren Hays to share an updated company presentation and discuss Immutep's latest developments.

Marc spoke about:
- Progress of the pivotal TACTI-004 Phase 3 trial in first-line non-small cell lung cancer, run in collaboration with Merck/MSD
- The company’s broader oncology and autoimmune pipeline, including the IMP761 program
- Key milestones and catalysts to watch for the remainder of 2025 and beyond

Watch the full discussion here: http://bit.ly/4673Wrb

Immutep (ASX:IMM, NASDAQ:IMMP) is developing late-stage immunotherapies for cancer and autoimmune disease centred on the LAG-3 protein. Marc Voigt, CEO, says the company is leveraging its diversified pipeline of five programs, including lead candidate eftilagimod alpha (efti) in oncology and IMP761....

08/09/2025

Immutep Limited CEO Marc Voigt will be joining the ShareCafe- Sip and Learn webinar this Thursday, 11 September at 12:30pm AEST.

Marc will deliver a company presentation and take part in the Q&A session.

Use this link to register if you'd like to join in!

This free webinar gives viewers the opportunity to hear from and engage with a range of ASX-listed micro/small cap company's. Company presentations will come from: - Etherstack (ASX:ESK) - Olympio Metals (ASX:OLY) - Rural Funds Group (ASX:RFF) - Immutep (ASX:IMM) Time: 12:30 PM AEST Day: Thursday, 1...

08/09/2025

Immutep Limited is pleased to announce an abstract for the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting taking place 12-15 November 2025, in Boca Raton, Florida.

For more details see https://lnkd.in/gZVbAdTw

29/08/2025

Immutep Limited is pleased to share its 2025 Annual Report today. Read the full report here: http://bit.ly/426U4em

Chairman Dr Russell Howard said:

"FY26 promises to be another year of meaningful progress. You can expect continued momentum for TACTI-004, updates from AIPAC-003, INSIGHT-003, and EFTISARC-NEO, as well as further advancement in our autoimmune portfolio with IMP761.

Our team remains focused on developing innovative immunotherapies that offer new hope to patients with cancer and autoimmune diseases."

The Immutep team is grateful for the continued support of our shareholders and looks forward to keeping them informed of key milestones along the way.

27/08/2025

Immutep Limited's CEO Marc Voigt joined Ausbiz's Nadine Blayney for a discussion covering a variety of topics including progress on the registrational TACTI-004 Phase 3 trial in non-small cell lung cancer, recent FDA feedback on late-stage clinical development of efti in head & neck cancer (CPS

Marc Voigt CEO of biotech Immutep (ASX: IMM) states recent clinical trial results for cancer drug, particularly in the first-line treatment of head and neck cancer, show promise. Voigt also highlights ongoing phase three trials in non-small cell lung cancer as a key focus for Immutep, positioning...

25/08/2025

IImmutep Limiteds CEO, Marc Voigt spoke with 77NEWS Perthas Immutep's pivotal Tacti-004 Phase III trial opens to patients in Western Australia.

Globally the Phase III trial will recruit over 750 patients across more than 150 clinical sites. This final stage of testing is focused on advanced and metastatic non-small cell lung cancer ( ) as a first-line treatment option after diagnosis.

For more information on the trial visit: https://immutep-lungcancer-trial.com/

21/08/2025

Immutep Limited's CEO Marc Voigt recently joined the Ausbiz Investor Connect session where he provided an update on the company’s pivotal TACTI-004 Phase 3 trial in first line , its clinical-stage IMP761 immunotherapy for autoimmune diseases, upcoming milestones, and more.

Watch the full video here: http://bit.ly/4mNIo8d

CEO Marc Voigt from Immutep (ASX: IMM) highlights the company’s clinical pipeline, focusing on immunotherapy treatments for cancer and autoimmune diseases.The company’s leading asset, eftilagimod alpha, is now at phase three clinical trial stage in first-line non-small cell lung cancer...

14/08/2025

We’re pleased to announce that Immutep Limited CEO Marc Voigt will join the Ausbiz Investor Connect session on Tuesday, 19 August at 1 pm AEST!

Join us for an insightful conversation and the opportunity to learn more about Immutep’s progress and strategy.

Register here: https://info.ausbiz.com.au/ausbiz-capital-event-aug-2025

05/08/2025

Immutep Limited has received positive and constructive feedback from the US FDA regarding potential late stage clinical development of eftilagimod alfa for first line treatment of head and neck squamous cell carcinoma patients with PD-L1 expression below 1 (CPS